EFFECTIVENESS OF METFORMIN IN PREVENTING EARLY PREGNANCY LOSS IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME

Mapping Intimacies ◽

10.36106/ijsr/2002182 ◽

2019 ◽

pp. 1-4

Author(s):

Deepali Janugade

Keyword(s):

Pregnant Women ◽

Early Pregnancy ◽

Pregnancy Loss ◽

Polycystic Ovary ◽

Free Testosterone ◽

Serum Glucose ◽

Control Group ◽

Early Pregnancy Loss ◽

Metformin Therapy ◽

Metformin Group

OBJECTIVE : To evaluate the effectiveness of metformin therapy in preventing early pregnancy loss in pregnant women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS : This is a prospective cohort study conducted in the Obstetric Department of Krishna Institute of Medical Sciences, Karad, Maharashtra, India for a period of 2 years. This study involved 100 nondiabetic pregnant women with PCOS. They were divided into two groups, namely, the group that received metformin throughout pregnancy (metformin group) and the group that got pregnant but, did not receive metformin (control group). A comparison was made between the two groups of patients with respect to certain basal characteristics (age, body mass index, previous obstetric outcome, serum glucose with free testosterone). Statistical analysis was performed using Chi-square test to compare the differences between the two groups. RESULTS : There were 50 patients who received metformin during pregnancy (metformin group) compared with 50 patients who did not receive the treatment (control group). The rate of early pregnancy loss in the metformin group was 10% (5/50) compared with 36% (18/50) in the control group (p < 0.001). For patients in the metformin group with a history of previous miscarriage, the rate of pregnancy loss was 45% (35 cases/50 pregnancies). CONCLUSION : Metformin therapy in pregnant women with PCOS was associated with a significant reduction in the rate of early pregnancy loss

Download Full-text

Incidence of Early Pregnancy Loss in Poly Cystic Ovary Syndrome Patients With /Without Metformin Therapy: A Comparative Study

Journal of Advances in Medicine and Medical Research ◽

10.9734/jammr/2020/v32i2430751 ◽

2020 ◽

pp. 55-62

Author(s):

Basma S. Ibrahem ◽

Amal A. El Syokar ◽

Ahmed M. Ossman ◽

Tarek M. El-Saba

Keyword(s):

Polycystic Ovary Syndrome ◽

Early Pregnancy ◽

Pregnancy Loss ◽

Polycystic Ovary ◽

Control Group ◽

Study Group ◽

Metformin Treatment ◽

Early Pregnancy Loss ◽

Ovary Syndrome ◽

Metformin Therapy

Background: The most prominent source of anovulatory infertility in the world is polycystic ovary syndrome. Getting pregnant these days has a larger risk of early maternal death than in the general population. It induces symptoms in about five and ten percent of women of reproductive age (12-45 years old). Women that are insulin tolerant are more prone to have Elevated Insulin levels, Polycystic OVARIES and Hyperandrogens. They are at risk for suboptimal reproductive activity attributable to compromising ovarian function and hormonal equilibrium. The aim of this research was to determine the prevalence of late pregnancy failure in women with Polycystic Ovary Syndrome (PCOS) taking metformin as compared to women who don't take it. Materials and Methods: This case control-controlled study included 100 females and divided in to two groups. Each group composed of 50 patients and the patients were distributed in each group by simple Randomization method. Results: There was no significant difference between control and study group regarding todescriptive data. Association between rate of pregnancy loss and metformin treatment early pregnancy loss was significantly frequent in control group than in study group with metformin treatment. Gestational age (weeks)at which pregnancy loss occurred is significantly higher in study group than in control group. The rate of early pregnancy loss among studied groups is significantly lower than in control group. Conclusion: Metformin therapy in pregnant women with polycystic ovary syndrome was associated with a significant reduction in the rate of early pregnancy loss. It was well tolerated by patients with a minimum of side effects. However, extended studies are required to evaluate its effect on further pregnancy complications and fetal outcomes.

Download Full-text

The Chemical Pregnancy

Revista de Chimie ◽

10.37358/rc.19.11.7652 ◽

2019 ◽

Vol 70 (11) ◽

pp. 3818-3823

Author(s):

Mihai Cristian Dumitrascu ◽

Madalina Iliescu ◽

Razvan Cosmin Petca ◽

Florica Sandru ◽

Claudia Mehedintu ◽

...

Keyword(s):

Risk Factors ◽

Early Pregnancy ◽

Pregnancy Loss ◽

Inhaled Corticosteroids ◽

Antihypertensive Drugs ◽

Polycystic Ovary ◽

Antidepressant Medication ◽

Chronic Hypertension ◽

Early Pregnancy Loss ◽

Multiple Risk Factors

The chemical pregnancy is an early pregnancy loss occurring shortly after implantation. 50-75% of all miscarriages are considered to be chemical pregnancies. Although the pregnancy test is positive, the fetus cannot be detected on ultrasounds; it can be asymptomatic or it can have menstrual-like cramping and bleeding. There are numerous risk factors associated with miscarriage, such as: epidemiological, genetic, anatomical, endometrial, endocrine and immune factors, infections, inherited thrombophilia and antiphospholipid syndrome. Many drugs are related with spontaneous miscarriage, significant evidence being found for nonsteroidal anti-inflammatory drugs, inhaled corticosteroids, antidepressant medication, antiepileptic and antihypertensive drugs, the artemisinin-based combination therapy and for the diclofenac/misoprostol combination. Besides the common diseases like asthma, chronic hypertension, chronic kidney disease, thyroid disorders, diabetes mellitus, polycystic ovary syndrome and rheumatoid arthritis, there was also found a higher correlation with the risk of miscarriage for the Zika Virus infection. In conclusion, chemical pregnancy is a type of early pregnancy loss which usually doesn�t need prevention, associated with multiple risk factors.

Download Full-text

Quantitative Proteomics Analysis of Altered Protein Expression in the Placental Villous Tissue of Early Pregnancy Loss Using Isobaric Tandem Mass Tags

BioMed Research International ◽

10.1155/2014/647143 ◽

2014 ◽

Vol 2014 ◽

pp. 1-9 ◽

Cited By ~ 4

Author(s):

Xiaobei Ni ◽

Xin Li ◽

Yueshuai Guo ◽

Tao Zhou ◽

Xuejiang Guo ◽

...

Keyword(s):

Protein Expression ◽

Pregnant Women ◽

Early Pregnancy ◽

Proteomic Analysis ◽

Pregnancy Loss ◽

Tandem Mass ◽

Pathophysiological Mechanism ◽

Early Pregnancy Loss ◽

Expression Levels ◽

Tandem Mass Tags

Many pregnant women suffer miscarriages during early gestation, but the description of these early pregnancy losses (EPL) can be somewhat confusing because of the complexities of early development. Thus, the identification of proteins with different expression profiles related to early pregnancy loss is essential for understanding the comprehensive pathophysiological mechanism. In this study, we report a gel-free tandem mass tags- (TMT-) labeling based proteomic analysis of five placental villous tissues from patients with early pregnancy loss and five from normal pregnant women. The application of this method resulted in the identification of 3423 proteins and 19647 peptides among the patient group and the matched normal control group. Qualitative and quantitative proteomic analysis revealed 51 proteins to be differentially abundant between the two groups (≥1.2-fold, Student'st-test,P<0.05). To obtain an overview of the biological functions of the proteins whose expression levels altered significantly in EPL group, gene ontology analysis was performed. We also investigated the twelve proteins with a difference over 1.5-fold using pathways analysis. Our results demonstrate that the gel-free TMT-based proteomic approach allows the quantification of differences in protein expression levels, which is useful for obtaining molecular insights into early pregnancy loss.

Download Full-text